Immuron Limited (IMRN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Immuron Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Immuron Limited (IMRN) has returned 1.61% so far this year and -56.96% over the past 12 months.

Based on dividend-adjusted daily data since Jun 9, 2017, IMRN's average daily return is +0.37%, while the average monthly return is +0.76%. At this rate, your investment would double in approximately 7.6 years.

Historically, 38% of months were positive and 62% were negative. The best month was Jun 2020 with a return of +250.3%, while the worst month was Dec 2025 at -55.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, IMRN closed higher 41% of trading days. The best single day was Jun 9, 2020 with a return of +852.4%, while the worst single day was Jun 10, 2020 at -50.6%.

Immuron Limited has an annualized alpha of 140.67%, beta of 0.41, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since June 12, 2017.

• This stock participated in 198.83% of S&P 500 Index downside but only 88.76% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.41 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IMRN ranks 10 for risk / return — in the bottom 10% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Immuron Limited (IMRN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Immuron Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immuron Limited was 96.50%, occurring on Mar 23, 2026. The portfolio has not yet recovered.

The current Immuron Limited drawdown is 96.13%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Immuron Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Immuron Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.